Summary
Thermo Fisher Scientific Inc. (TMO) announced significant leadership changes within its executive ranks via an 8-K filing on September 27, 2021, effective with events on September 23, 2021. These changes involve the planned retirements of two key executives: Mark Stevenson, Executive Vice President and Chief Operating Officer, who will retire on March 18, 2022, and Syed Jafry, Senior Vice President, Regions, who will retire on March 31, 2022. The company has proactively appointed successors to ensure a smooth transition in critical operational roles. Michel Lagarde has been appointed as the new Executive Vice President and Chief Operating Officer, effective January 1, 2022, taking over from Mr. Stevenson. Mr. Lagarde brings extensive experience, having previously led the Pharma Services business and held leadership roles at Patheon. Additionally, Gianluca Pettiti has been appointed as an Executive Vice President, effective December 27, 2021, and currently leads the Specialty Diagnostics business. These appointments reflect Thermo Fisher's strategy of internal succession planning for its senior leadership.
Key Highlights
- 1Planned retirement of COO Mark Stevenson effective March 18, 2022.
- 2Planned retirement of SVP Regions Syed Jafry effective March 31, 2022.
- 3Appointment of Michel Lagarde as EVP and COO, effective January 1, 2022.
- 4Michel Lagarde has prior experience leading Pharma Services and Patheon.
- 5Appointment of Gianluca Pettiti as EVP, effective December 27, 2021.
- 6Gianluca Pettiti currently leads the Specialty Diagnostics business and has experience leading Biosciences and the China business.